MedTech Current regulatory intelligence and device recall publications for United Kingdom.
The UK government intends to recognise EU MDR- and IVDR-compliant devices indefinitely in Great Britain, with separate arrangements for MDD legacy devices. Legislation remains subject to parliamentary approval; UKCA and domestic registration and surveillance obligations continue.
MHRA plans an adaptive framework for AI medical devices, a Centre for AI and Digital Health, and stronger lifecycle data and traceability. The 14 October strategy sets future priorities; planned UDI measures remain subject to the parliamentary process.
The new hub brings together existing guidance and publications on real-world evidence. Device developers should distinguish the hub’s launch from the dates, status and scope of its linked resources.
MHRA’s September MRI guidance update corrects diagrams and other details; the fifth-edition rewrite was introduced in July. The current guidance explains distinct questions about 7 T heating and implants, hearing-protection ratings and quench venting, rather than a single new September safety regime.
UK guidance lists CPTPP entry into force with Canada from September 1, 2026, following earlier entry with other parties. Medtech businesses should verify origin, destination tariffs and the approval scope of conformity assessment bodies before relying on benefits.
The UK Department of Health and Social Care published a Health Bill fact sheet outlining primary legislative powers for the MHRA to directly license medical devices and strengthen global safety data sharing.
MHRA has updated its guidance on medicine parallel import licence applications with more detailed instructions on submission, supporting documents, sample scans, packaging, company functions, and its one-RFI assessment approach. The guidance applies to medicines and should not be treated as a medical-device parallel-import licensing pathway.
OPSS refreshed the featured recalls on its Product Recalls and Alerts page on 25 August 2026. The update is routine rather than a new recall rule, and the portal expressly excludes medicines and medical devices, which remain subject to separate MHRA safety-alert and recall channels.
The 25 August 2026 update to the UK AI Research Resource page only adds AMD to the partner list; it does not introduce a new AI or digital-health regulatory requirement. For healthcare AI and R&D teams, the more important opportunity is the existing access to Isambard-AI and Dawn through routes such as Rapid Access and Gateway.
The Department for Business and Trade updated its Great Britain UKCA / CE market guide on August 21, 2026, with a limited wording change to the declaration-of-conformity template. The wider guide remains a useful operating reference for non-medical products covered by the continued-recognition framework, including CE access, Fast-Track UKCA, marking placement, importer details, and labelling flexibilities.